Compare Abbott Laboratories (ABT) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Raytheon Technologies Corp — how do they compare? Abbott Laboratories trades at $95.81 (market cap $166.94B), while Raytheon Technologies Corp trades at $197.27 (market cap $270.48B). The key difference: Raytheon Technologies Corp is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | RTX | |
|---|---|---|
Market Cap | $166.94B | $270.48B |
Sector | Health | Industrials |
52-Week High | $136.62 | $212.16 |
52-Week Low | $82.57 | $144.91 |
Enterprise Value | $193.69B | $302.60B |
Dividend Yield | 2.63% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
RTX trades at $201.37, up 1.06% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats and a $515 million Navy contract for SPY-6 radars highlight operational momentum. Revenue grew to $88.6 billion in 2025, with net income margin improving to 8.03%. The stock is near its consensus price target of $213, with no sell ratings among 26 analysts.
The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation multiples and geopolitical dependencies. Upside potential exists if the company maintains its earnings beat streak and capitalizes on increased defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
